TB/HIV Project News
Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing –
November 22, 2013 — Approval of and access to delamanid are crucial while further research is pending —
NEW YORK, NY, USA – Treatment Action Group (TAG) congratulates the Committee for Medicinal Products for Human Use (CHMP) for its recommendation to the European Medicines Agency (EMA) to grant marketing approval to delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) now in phase III clinical trials. MDR-TB treatment options that do not include new drugs are long, toxic, difficult to tolerate, and often ineffective.
October 30, 2013 – Activists stormed the stage at the World Health Organization (WHO) sponsored Stop TB Symposium during the 44th Union World Conference on Lung Health. TAG's TB Project Director Colleen Daniels called for global action and a new global attitude in the fight against TB.
Tuberculosis: Behind the Numbers Video Series
- A Double Blow: Private-Sector Funding for TB Research Drops Sharply Amid Severe Public-Sector Budget Cuts
As Threat of Drug-Resistance Grows, Big Pharma Decreases Investments in TB research by 22 Percent
October 29, 2013 – Paris, France – The 2013 Report on Tuberculosis Research Funding Trends, 2005–2012 finds that funding for tuberculosis research and development (TB R&D) dropped by US$30.4 million compared with 2011—the first time funding has fallen since TAG began tracking investments in 2005. Funding declined for diagnostic, drug, vaccine, and operational research, increasing the likelihood that new tools to fight TB will remain out of reach for the 8.7 million people who develop TB each year.
- October 2013 – Mark Harrington, executive director of TAG, was featured in an online panel discussion about the global crisis of drug-resistant tuberculosis (DR-TB). The webcast, New Approaches to Drug-Resistant Tuberculosis, was hosted by Doctors Without Borders/Médecins Sans Frontières (MSF) and New York Times science writer Denise Grady. The panel comprised health care workers and patient advocates working to improve treatment for people living with DR-TB, including Dr. Grania Brigden, TB advisor, MSF Access Campaign; Cathy Hewison, TB medical advisor at MSF; Mark Harrington, executive director of Treatment Action Group; and Evaline Kibuchi, senior TB advocacy manager at the Kenya AIDS NGO Consortium (KANCO).
- Cascades: Improving TB Care
Please join Treatment Action Group, Partners In Health, Médecins Sans Frontières, the Stop TB Partnership and the Department of Global Health and Social Medicine at Harvard Medical School for a satellite symposium at the 44th Union World Conference on Lung Health.
Friday, November 1, 2013
18h00 – 21h00
Hyatt Regency Paris Etoile
3, Place du Général Koenig
Batignolles/ Longchamp Room
- First-Ever Targeted Roadmap Outlines Steps to End Childhood TB Deaths
Cost to end deaths from childhood TB estimated to be at least US$120 million annually
WASHINGTON D.C. | October 1, 2013 -- The deaths of more than 74 000 children from tuberculosis (TB) could be prevented each year through measures outlined in the first ever action plan developed specifically on TB and children.
ROADMAP FOR CHILDHOOD TB: TOWARDS ZERO DEATHS
The World Health Organization, the International Union Against Tuberculosis and Lung Disease, the Stop TB Partnership and other partners will launch a roadmap outlining the path towards zero deaths from childhood tuberculosis.
Tuesday, 1 October 2013
11:00 a.m. Press Conference
2:00 p.m. Workshop
PATH, 455 Massachusetts Ave, NW, Suite 1000
Washington, DC 20001
Please join us for the launch.
- Treatment Action Group Criticizes European Refusal of New Drug to Fight Tuberculosis
— Approval of and access to delamanid is crucial while further research is pending —
July 29, 2013 – Treatment Action Group (TAG) is disappointed by the failure of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB).